If you've ever thought about investing in the gene-editing biotech space, Editas Medicine (NASDAQ: EDIT) and CRISPR Therapeutics (NASDAQ: CRSP) are doubtlessly familiar to you. While neither company is selling anything as of yet, in a few short months that's likely to change for one of the pair. 

But given that a third rival, Bluebird Bio, is also competing in this market, it's not enough for one to commercialize its candidate faster than the other. It will also need to beat Bluebird to succeed. So, let's analyze each to determine which is the better gene-editing stock in light of the market conditions they're likely to face once their products are out the door, assuming they get there.

CRISPR Therapeutics is currently closer to commercializing its medicine than Editas, so it has a major edge. Its exa-cel program, which could treat both beta-thalassemia and sickle cell disease (SCD), is done with its phase 3 trials already. The Food and Drug Administration (FDA) will determine in early December whether to approve exa-cel for SCD, and it's expected to decide near the end of the first quarter 2024 for beta-thalassemia.

Continue reading

Source Fool.com